ANO6

Across TCGA pan-cancer cohorts, ANO6 mass-spec protein is linked to patient survival in 8 of 34 cancer types, making it a survival-associated ANO6 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ANO6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ANO6 expression acts as an unfavorable survival marker.

PDAC, CCRCC, and COAD are the cancer types where ANO6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.650	0.910	<.001	54	view →
CCRCC	OS	Median	All	0.740	0.925	<.001	24	view →
COAD	DFS	Median	III,IV	0.829	1.000	.027	12	view →
UCEC	DFS	Quartile	II,III,IV	0.509	1.000	.025	4	view →
LSCC	DFS	Median	All	0.482	0.888	.016	3	view →
LUAD	DFS	Median	II,III,IV	0.191	0.720	.008	3	view →
GBM	DFS	Tertile	All	0.250	0.479	.046	2	view →
HNSC	OS	Median	IV	0.931	1.000	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

ANO6–PDAC (DFS)

Open the PDAC breakdown →